Rivastigmine in the treatment of dementia with Lewy bodies: Preliminary findings from an open trial

International Journal of Geriatric Psychiatry

Volumn 15, Issue 5, 2000, Pages 387-392

  McKeith, Ian G ^a   Grace, Janet B ^a   Walker, Zuzana ^b   Byrne, E Jane ^c   Wilkinson, David ^d   Stevens, Timothy ^e   Perry, Elaine K ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b St Margaret's Hospital   (United Kingdom)

^c WITHINGTON HOSPITAL   (United Kingdom)

^d MOORGREEN HOSPITAL   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cholinesterase inhibitor; Dementia with Lewy bodies; Treatment

Indexed keywords

CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

ADULT; AGITATION; APATHY; ARTICLE; CHOLINESTERASE INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; DELUSION; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HALLUCINATION; HUMAN; LEWY BODY; MALE; PARKINSONISM;

EID: 0034043638     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1166(200005)15:5<387::AID-GPS131>3.0.CO;2-9     Document Type: Article

References (23)

1. Corey-Bloom, J., Anand, R. and Veach, J., for the ENA 713 B352 Study Group (1998) A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int. J. Geriatr. Psychopharmacol. 1, 55-65.
2. Cummings, J. L., Gorman, D. G. and Schapira, J. (1993) Physostigmine ameliorates the delusions of Alzheimer's disease. Biol. Psychiat. 33, 536-541.
3. Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. and Gornbein, J. (1994) The Neuropsychiatric Inventory - comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
4. Cummings, J. L., Cyrus, P. A., Mas, J., Orazem, J. and Gulanski, B. and the Metrifonate Study Group (1998) Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 50, 1214-1221.
5. Fahn, S. and Elton, R. (1987) Unified Parkinson's Disease Rating Scale. In Recent Developments in Parkinson's Disease (S. Fahn, C. D. Marsden and D. Calne, Eds). Macmillan, New York, pp. 153-163.
6. Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975) "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. 12, 189-198.
7. Holmes, C., Cairns, N., Lantos, P. and Mann, A. (1999) Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br. J. Psychiat. 174, 45-50.
8. Hutchinson, M. and Fazzini, E. (1996) Cholinesterase inhibition in Parkinson's disease. J. Neurol. Neurosurg. Psychiat. 61, 324-325.
9. Kaufer, D. I., Catt, K. E., Lopez, O. L. and DeKovsky, S. T. (1998) Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 51, 1512.
10. Levy, R., Eagger, S., Griffiths, M., Perry, E. K., Honovar, M., Dean, M. and Lantos, P. (1994) Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 343, 176.
11. McKeith, I., Fairbairn, A., Perry, R., Thompson, P. and Perry, E. (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br. Med. J. 305, 673-678.
12. McKeith, I. G., Harrison, R. W. S. and Ballard, C. G. (1995) Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 346, 699.
13. McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., Lennox, G., Quinn, N. P., Edwardson, J. A., Ince, P. G., Bergeron, D., Burns, A., Miller, B. L., Lovestone, S., Collerton, D., Jansen, E. N. H., Ballard, C., de Vos, R. A. I., Wilcock, G. K., Jellinger, K. A. and Perry, R. H. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 47, 1113-1124.
14. Mega, M. S., Masterman, D. L., Benson, F., Vinters, H. V., Tomiyasu, U., Craig, A. H., Foti, D. J., Kaufer, D., Schame, D. W., Fairbanks, L. and Cummings, J. L. (1996) Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology 47, 1403-1409.
15. Perry, E. K. and Perry, R. H. (1996) Altered consciousness and transmitter signalling in Lewy body dementia. In Dementia with Lewy Bodies (R. Perry, I. McKeith and E. Perry, Eds). Cambridge University Press, New York, pp. 397-413.
16. Perry, R. H., Irving, D., Blessed, G., Fairbairn, A. and Perry, E. K. (1989) Clinically and neuropathologically distinct form of dementia in the elderly. Lancet 1, 66.
17. Perry, R. H., Jaros, E., Ince, P., Scoones, D., Fairbairn, A., Thompson, P., Ballard, C. and McKeith, I. (1998) Dementia with Lewy bodies: diagnostic accuracy using Consensus criteria. Neurobiol. Aging 19(4S), S203.
18. Piggott, M. A., Perry, E. K., McKeith, I. G., Marshall, E. and Perry, R. H. (1994) Dopamine D2 receptors in patients with severe neuroleptic sensitivity. Lancet 343, 1044-1045.
19. Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R. and Friedhoff, L. T. and the Donepezil Study Group (1998) A 24 week double blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50, 136-145.
20. Scully, R. E., Mark, E. J., McNeely, W. F., Ebeling, S. H. and Philips, L. D. (1998) Case records of the Massachusetts General Hospital. New Engl. J. Med. 338, 603-610.
21. Shea, C., MacKnight, C. and Rockwood, K. (1998) Donepezil for treatment of Dementia with Lewy bodies: a case series of nine cases. Int. Psychogeriatr. 10, 229-238.
22. Walker, Z., Grace, J., Overshot, R., Satarasinghe, S., Swann, A., Katona, C. L. E. and McKeith, I. G. (1999) Olanzapine in dementia with Lewy bodies: a clinical study. Int. J. Geriatr. Psychiat. 14, 459-466.
23. Wilcock, G. K. and Scott, M. I. (1994) Tacrine for senile dementia of Alzheimer's or Lewy body type. Lancet 344, 544.